441 related articles for article (PubMed ID: 22711276)
1. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
Zhao L; Chen CN; Hajji N; Oliver E; Cotroneo E; Wharton J; Wang D; Li M; McKinsey TA; Stenmark KR; Wilkins MR
Circulation; 2012 Jul; 126(4):455-67. PubMed ID: 22711276
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic efficacy of valproic acid in a combined monocrotaline and chronic hypoxia rat model of severe pulmonary hypertension.
Lan B; Hayama E; Kawaguchi N; Furutani Y; Nakanishi T
PLoS One; 2015; 10(1):e0117211. PubMed ID: 25629315
[TBL] [Abstract][Full Text] [Related]
3. Response to letter regarding article, “histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid”.
Zhao L; Chen CN; Hajji N; Oliver E; Cotroneo E; Wharton J; Wilkins MR; Wang D; Li M; Stenmark KR; McKinsey TA; Buttrick P
Circulation; 2013 Apr; 127(14):e540. PubMed ID: 23691553
[No Abstract] [Full Text] [Related]
4. Letter by Bogaard et al regarding article, "histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid".
Bogaard HJ; Mizuno S; Voelkel NF
Circulation; 2013 Apr; 127(14):e539. PubMed ID: 23569123
[No Abstract] [Full Text] [Related]
5. Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism.
Cavasin MA; Demos-Davies K; Horn TR; Walker LA; Lemon DD; Birdsey N; Weiser-Evans MC; Harral J; Irwin DC; Anwar A; Yeager ME; Li M; Watson PA; Nemenoff RA; Buttrick PM; Stenmark KR; McKinsey TA
Circ Res; 2012 Mar; 110(5):739-48. PubMed ID: 22282194
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary artery smooth muscle cell proliferation and migration in fetal lambs acclimatized to high-altitude long-term hypoxia: role of histone acetylation.
Yang Q; Lu Z; Ramchandran R; Longo LD; Raj JU
Am J Physiol Lung Cell Mol Physiol; 2012 Dec; 303(11):L1001-10. PubMed ID: 23043075
[TBL] [Abstract][Full Text] [Related]
7. Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats.
Bogaard HJ; Mizuno S; Hussaini AA; Toldo S; Abbate A; Kraskauskas D; Kasper M; Natarajan R; Voelkel NF
Am J Respir Crit Care Med; 2011 May; 183(10):1402-10. PubMed ID: 21297075
[TBL] [Abstract][Full Text] [Related]
8. Dissecting histone deacetylase role in pulmonary arterial smooth muscle cell proliferation and migration.
Galletti M; Cantoni S; Zambelli F; Valente S; Palazzini M; Manes A; Pasquinelli G; Mai A; Galiè N; Ventura C
Biochem Pharmacol; 2014 Sep; 91(2):181-90. PubMed ID: 25063234
[TBL] [Abstract][Full Text] [Related]
9. Restoration of impaired endothelial myocyte enhancer factor 2 function rescues pulmonary arterial hypertension.
Kim J; Hwangbo C; Hu X; Kang Y; Papangeli I; Mehrotra D; Park H; Ju H; McLean DL; Comhair SA; Erzurum SC; Chun HJ
Circulation; 2015 Jan; 131(2):190-9. PubMed ID: 25336633
[TBL] [Abstract][Full Text] [Related]
10. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
11. IGF-1 signaling in neonatal hypoxia-induced pulmonary hypertension: Role of epigenetic regulation.
Yang Q; Sun M; Ramchandran R; Raj JU
Vascul Pharmacol; 2015 Oct; 73():20-31. PubMed ID: 25921925
[TBL] [Abstract][Full Text] [Related]
12. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
Beyer M; Kiweler N; Mahboobi S; Krämer OH
Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
[TBL] [Abstract][Full Text] [Related]
13. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo.
Singh T; Prasad R; Katiyar SK
Epigenetics; 2013 Jan; 8(1):54-65. PubMed ID: 23221619
[TBL] [Abstract][Full Text] [Related]
15. Role of histone deacetylases in regulation of phenotype of ovine newborn pulmonary arterial smooth muscle cells.
Yang Q; Dahl MJ; Albertine KH; Ramchandran R; Sun M; Raj JU
Cell Prolif; 2013 Dec; 46(6):654-64. PubMed ID: 24460719
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of histone deacetylases protects septic mice from lung and splenic apoptosis.
Takebe M; Oishi H; Taguchi K; Aoki Y; Takashina M; Tomita K; Yokoo H; Takano Y; Yamazaki M; Hattori Y
J Surg Res; 2014 Apr; 187(2):559-70. PubMed ID: 24290430
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA
Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049
[TBL] [Abstract][Full Text] [Related]
18. Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009.
Hsieh IN; Liou JP; Lee HY; Lai MJ; Li YH; Yang CR
Cell Death Dis; 2014 Apr; 5(4):e1166. PubMed ID: 24722291
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibition by suberoylanilide hydroxamic acid: a therapeutic approach to treat human uterine leiomyoma.
Carbajo-García MC; García-Alcázar Z; Corachán A; Monleón J; Trelis A; Faus A; Pellicer A; Ferrero H
Fertil Steril; 2022 Feb; 117(2):433-443. PubMed ID: 34809976
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic evidence of an Ac/Dc axis by VPA and SAHA.
Lunke S; Maxwell S; Khurana I; K N H; Okabe J; Al-Hasani K; El-Osta A
Clin Epigenetics; 2021 Mar; 13(1):58. PubMed ID: 33743782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
